Armando Anido

Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) released financial results for the first quarter ended March 31, 2023, revealing research and development expenses were $7.1 million for the first quarter of 2023, including stock-based compensation of $400,000. General and administrative expenses were $...

Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) released financial results for the fourth quarter and full year ended December 31, 2022, revealing research and development expenses were $21.1 million for full year 2022, including stock-based compensation of $2.0 million. Q4 and Full Year 2022...

Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), announced the publication of a paper entitled, “Role of the endocannabinoid system in fragile X syndrome: potential mechanisms for benefit from cannabidiol treatment,” in the Journal of Neurodevelopmental Disorders. The review of evidence...

Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) presented positive long-term 38-week data from the phase 2 INSPIRE trial with Zygel in children and adolescents with 22q11.2 deletion syndrome. The data were presented in a poster at the 61st annual meeting of the American College of...

Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), released financial results for the second quarter ended June 30, 2022. Q2 2022 Financial Highlights Net loss for the second quarter of 2022 was $9.9 million, with basic and diluted loss per share of $(0.24). Research and development expenses were $...

Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), reported financial results for the first quarter ended March 31, 2022, revealing net loss of $8.5 million. Research and development expenses were $5.1 million for the first quarter of 2022, including stock-based compensation of $0.5 million. General and...

Manufacturer of transdermal cannabinoid therapies for neuropsychiatric disorders, Zynerba Pharmaceuticals, Inc. Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) reported Tuesday financial results for the fourth quarter and full year ended December 31, 2021. “In 2022, we look to build on last...

Manufacturer of transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), completed enrollment for the 14-week Phase 2 INSPIRE trial of Zygel (Transdermal CBD Gel) in the treatment of behavioral symptoms of 22q11.2 deletion...

Cresco Labs Taps Megan Kulick To Serve As VP Of Investor Relations Cresco Labs (OTC: CRLBF) appointed Megan Kulick to the role of senior vice president of investor relations. Kulick has over 20 years of experience in investor relations, equity research, and portfolio management at bulge...

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) has appointed Albert P. Parker, an accomplished industry executive with over 25 years of pharmaceutical, biotech and healthcare experience, as chief legal officer and corporate secretary. He will assume the duties of Suzanne Hanlon who will retire from...

Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) disclosed Wednesday its first-quarter net loss of $8.0 million or a loss of 20 cents per share, compared to $12.34 million in the same period of 2020 or a loss of 53 cents per share. First Quarter Highlights Cannabinoid-focused pharmaceutical company...

Benzinga recently had the chance to speak with Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) CEO Armando Anido about the impact the U.S. election will have on the company, the potential of Zynerba’s two main drug candidates and the health of Zynerba’s balance sheet. The Election's...